Recognising colchicine role in cardiovascular disease prevention


Early initiation of low-dose colchicine after MI reduces the risk of ischaemic cardiovascular events - benefits emerge early and continue to accrue

You will learn:
Gout and hyperuricaemia have been linked to an increased risk of coronary artery disease (CAD), heart failure and cardiovascular mortality (1)
Colchicine, as first-line therapy in both gout and pericarditis, has multiple anti-inflammatory actions
It is timeous for clinicians to review the latest results of colchicine clinical trials in CAD and myocardial infarction (MI) for consideration for very high-risk patients and for adoption in their daily practice
The recent 2021 European Society of Cardiology (ESC) guidelines on cardiovascular disease prevention in clinical practice provides a recommended framework for the use of colchicine.

To access this module, please register or login: